Nelson DB, Godoy MCB, Benveniste MF, Shewale JB, Spicer JD, Mitchell KG, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG , Roth JA, Antonoff MB
Pelacarsen, an LPA inhibitor, is heading for a Phase III readout in mid-2026 a data event that could define the entire LPA inhibitor class
Improved Energy : Many report feeling more energetic and motivated, thanks to the addition of B12
Dependent smokers will be enrolled in a double-blind, parallel-arm trial with laboratory endpoints
Gabe MBN, van der Velden WJC, Gadgaard S, et al
If Phase 3 confirms the Phase 2 numbers, retatrutide would represent a significant step beyond the current gold standard, not just an incremental improvement